The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature

Background: The human anti-IL-6 receptor antibody tocilizumab (TCZ) has been approved for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA). It is observed that CRP levels drop quickly after starting TCZ treatment. This may lead to misinterpretation of laboratory results when...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Mark Berman, Ronen Ben-Ami, Shlomo Berliner, Marina Anouk, Ilana Kaufman, Adi Broyde, Sara Borok, Ori Elkayam
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2021-03-01
סדרה:	Life
נושאים:	tocilizumab infection rheumatoid arthritis giant cell arteritis C-reactive protein inflammation
גישה מקוונת:	https://www.mdpi.com/2075-1729/11/3/258
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!